Needham & Company initiates coverage on February IPO Flexion Therapeutics (NASDAQ: FLXN) with a Buy rating and a price target ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE